Aspirin Attenuates Pulmonary Arterial Hypertension in Rats by Reducing Plasma 5-Hydroxytryptamine Levels

Cell Biochemistry and Biophysics

Volumn 61, Issue 1, 2011, Pages 23-31

  Shen, Lan ^a   Shen, Jieyan ^a   Pu, Jun ^a   He, Ben ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

5 HT; Aspirin; Monocrotaline; Pulmonary arterial hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; MONOCROTALINE; SEROTONIN;

ANIMAL; ARTICLE; BLOOD; BLOOD PRESSURE; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; HEART RATE; HEMODYNAMICS; MALE; MORTALITY; PATHOLOGY; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SPRAGUE DAWLEY RAT; SURVIVAL; THROMBOCYTE AGGREGATION;

ANIMALS; ASPIRIN; BLOOD PRESSURE; BODY WEIGHT; DISEASE MODELS, ANIMAL; HEART RATE; HEMODYNAMICS; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SURVIVAL ANALYSIS;

RATTUS;

EID: 80051471868     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-011-9156-x     Document Type: Article

References (24)

1. Tuder, R. M., Marecki, J. C., Richter, A., et al. (2007). Pathology of pulmonary hypertension. Clinics in Chest Medicine, 28(1), 23-42, vii.
2. Carlino, C., Tobias, J. D., Schneider, R. I., et al. (2010). Pulmonary hemodynamic response to acute combination and monotherapy with sildenafil and brain natriuretic peptide in rats with monocrotaline-induced pulmonary hypertension. American Journal of the Medical Sciences, 339(1), 55-59.
3. Gurtner, H. P. (1985). Aminorex and pulmonary hypertension. A review. Cor et Vasa, 27(2-3), 160-171.
4. MacLean, M. R., Herve, P., Eddahibi, S., et al. (2000). 5-hydroxytryptamine and the pulmonary circulation: Receptors, transporters and relevance to pulmonary arterial hypertension. British Journal of Pharmacology, 131(2), 161-168.
5. MacLean, M. R. (2007). Pulmonary hypertension and the serotonin hypothesis: Where are we now? International Journal of Clinical Practice Supplement, 156, 27-31.
6. Kanai, Y., Hori, S., Tanaka, T., et al. (1993). Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats. Cardiovascular Research, 27(9), 1619-1623.
7. Herve, P., Launay, J. M., Scrobohaci, M. L., et al. (1995). Increased plasma serotonin in primary pulmonary hypertension. American Journal of Medicine, 99(3), 249-254.
8. Guignabert, C., Raffestin, B., Benferhat, R., et al. (2005). Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation, 111(21), 2812-2819.
9. Hironaka, E., Hongo, M., Sakai, A., et al. (2003). Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovascular Research, 60(3), 692-699.
10. Tsai, T. H., Tsai, W. J., & Chen, C. F. (1995). Aspirin inhibits collagen-induced platelet serotonin release, as measured by microbore high-performance liquid chromatography with electrochemical detection. Journal of Chromatography. B Biomedical Applications, 669(2), 404-407.
11. De, C. F. (1990). The role of serotonin in thrombogenesis. Clinical Physiology and Biochemistry, 8(Suppl 3), 40-49.
12. Kentera, D., Susic, D., & Zdravkovic, M. (1979). Effects of verapamil and aspirin on experimental chronic hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. Respiration, 37(4), 192-196.
13. Delcroix, M., Melot, C., Lejeune, P., et al. (1992). Cyclooxygenase inhibition aggravates pulmonary hypertension and deteriorates gas exchange in canine pulmonary embolism. American Review of Respiratory Disease, 145(4 Pt 1), 806-810.
14. Schultze, A. E., & Roth, R. A. (1998). Chronic pulmonary hypertension-the monocrotaline model and involvement of the hemostatic system. Journal of Toxicology and Environmental Health Part B: Critical Reviews, 1(4), 271-346.
15. Eddahibi, S., Humbert, M., Fadel, E., et al. (2001). Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. Journal of Clinical Investigation, 108(8), 1141-1150.
16. Guignabert, C., Izikki, M., Tu, L. I., et al. (2006). Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circulation Research, 98(10), 1323-1330.
17. Morecroft, I., Pang, L., Baranowska, M., et al. (2010). In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovascular Research, 85(3), 593-603.
18. Newman, J. H., Fanburg, B. L., Archer, S. L., et al. (2004). Pulmonary arterial hypertension: Future directions: Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation, 109(24), 2947-2952.
19. Dumitrascu, R., Koebrich, S., Dony, E., et al. (2008). Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. BMC Pulmonary Medicine, 8, 25.
20. Ramos, M. F., Lame, M. W., Segall, H. J., et al. (2008). Smad signaling in the rat model of monocrotaline pulmonary hypertension. Toxicologic Pathology, 36(2), 311-320.
21. Vane, J. R., & Botting, R. M. (2003). The mechanism of action of aspirin. Thrombosis Research, 110(5-6), 255-258.
22. Johnson, S. R., Granton, J. T., & Mehta, S. (2006). Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest, 130(2), 545-552.
23. Shen, J., He, B., & Wang, B. (2005). Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension. Chest, 128(2), 714-719.
24. Robbins, I. M., Kawut, S. M., Yung, D., et al. (2006). A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 27(3), 578-584.